Senores Pharma Acquires 14 ANDAs from Dr. Reddy’s to Expand U.S. Market Presence

Senores Pharmaceuticals Limited (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreements to acquire 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy’s Laboratories (DRL) and its affiliates. The acquisition includes 13 USFDA-approved ANDAs and one pending approval.

Market Potential

The acquired ANDAs have a market opportunity of ~USD 421 million (MAT December 2024) as per IQVIA and around USD 1.13 billion (MAT September 2024) according to Symphony.

The acquisition will be funded using proceeds from SPL’s Initial Public Offering (IPO), aligning with its stated objectives in the Red Herring Prospectus. This move strengthens SPL’s presence in the U.S. generics market.

Commenting on the acquisition, the Managing Director of Senores Pharmaceuticals Limited, Mr Swapnil Shah, said, “We are glad to announce the acquisition of a basket of products from Dr Reddy’s. It spans across various therapeutic areas with growing consumption. The portfolio consists of controlled substances and general category of products.”

He further added, “These products can be distributed through multiple/diverse channels, with large requirements in government, retail and specialty clinics. This Portfolio of products significantly increases our product offering in the US, and also it has a significant value in other Regulated and Semi-Regulated markets of the world.”

About Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited (Senores) is a global, research-focused pharmaceutical company specialising in the development and manufacturing of a diverse range of pharmaceutical products. It primarily serves regulated and emerging markets, including the U.S. and Canada, across various therapeutic segments and dosage forms.

On March 5, 2025, Senores Pharmaceuticals share price opened at ₹564.00, up from its previous close of ₹562.50. At 9:45 AM, the share price of Senores Pharmaceuticals was trading at ₹576.15, up by 2.43% on the NSE.

Conclusion

With this acquisition, Senores Pharmaceuticals aims to expand its portfolio and enhance its growth trajectory in the U.S. pharmaceutical market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.